Eviva

What Eviva does

Eviva (legal entity: Puget Sound Surgical Center dba Eviva) is a private, single-site bariatric and medical weight loss practice founded in 2005 and headquartered in Shoreline, Washington. The practice specializes in surgical, endoscopic, and medical weight loss care for adults with obesity (BMI 27+), serving patients in the greater Seattle area and drawing individuals nationally and internationally. Eviva pioneered the world's first outpatient gastric sleeve procedure and is the most published bariatric Ambulatory Surgery Center (ASC) in the US, with research collaborations with Harvard and Mayo Clinic and feature publication at the IFSO 2022 World Congress.

The company's core product platform spans three surgical procedures — Gastric Sleeve (LapSleeve®), Gastric Bypass, and Gastric Band — plus revision surgery; endoscopic procedures (EndoSleeve/ESG, including the proprietary Endosleeve+ 8–10 suture protocol with ~23% total body weight loss, and Gastric Balloon); the 2026-launched MagDI (Magnetic Duodeno-Ileostomy); and a Medical Weight Loss Program built around FDA-approved GLP-1 injectables (Ozempic, Wegovy, Mounjaro) and oral agents. Supporting services include nutrition coaching, support groups, the healow patient portal, and BLISCare complication coverage integrated into self-pay packages.

The business model is a hybrid of insurance-billed and self-pay care. Self-pay packages (facility, surgeon, anesthesia, pre-op consults, 12 months of aftercare, and BLISCare) are bundled and financed through Cherry and CareCredit, with monthly payment examples of $548 (EndoSleeve), $813 (Gastric Sleeve), and $1,079 (Gastric Bypass). In-network status with Aetna, BCBS, Premera, Regence, UHC, and other Pacific Northwest payers provides the volume base, while out-of-pocket and financing-driven self-pay flows capture uninsured or out-of-state patients. Revenue is generated from one-time procedural fees, recurring medical weight loss subscriptions ($150/$75 per month), and ancillary cosmetic work, with multi-channel marketing (SEO, social media, virtual consultations, patient testimonials) driving direct patient acquisition.

Name

Eviva

Legal name

Puget Sound Surgical Center dba Eviva

Website

https://evivamd.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

Eviva is a private, single-site bariatric and medical weight loss practice in Shoreline, Washington that provides surgical (gastric sleeve, bypass, band), endoscopic (EndoSleeve, MagDI), and GLP-1-based medical weight loss care to adult obesity patients in the Pacific Northwest and beyond.

Ownership category

akta.pro rank

Product category

Bariatric and Weight Management Surgery Services

NAICS

Freestanding Ambulatory Surgical and Emergency Centers (621493), Offices of Physicians (6211), Diet and Weight Reducing Centers (812191)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Obesity Medicine & Weight Management (HLAKADAL)

akta.pro secondary industry

General Gastroenterology (HLAKAEAA)

Keywords

• Bariatric surgery
• Weight loss procedures
• Endoscopic sleeve gastroplasty
• Medical weight loss
• Gastric bypass

Headquarters

HQ city

Shoreline

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Surgical Weight Loss Procedures: Revenue from performing surgical weight loss procedures including gastric sleeve, gastric bypass, gastric band, and revisions. Procedures are billed to insurance or paid self-pay.
2. Endoscopic Weight Loss Procedures: Revenue from non-surgical endoscopic procedures including Endoscopic Sleeve Gastroplasty (ESG/EndoSleeve) and gastric balloon placements.
3. Medical Weight Loss Program: Revenue from FDA-approved weight loss medications (injectable and oral), ongoing monitoring, and dietitian consultations. Initial program costs $350 with $150/month provider follow-ups and $75/month dietitian visits.
4. Cosmetic Procedures: Revenue from cosmetic procedures including excess skin removal following significant weight loss.
5. Financing Partnerships: Partnership revenue share from Cherry and CareCredit financing options that enable patients to pay over time for procedures not covered by insurance.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels10 records

Core offering

Eviva is a bariatric and weight management medical practice that delivers surgical (Gastric Sleeve, Gastric Bypass, Gastric Band, revisions), endoscopic (Endoscopic Sleeve Gastroplasty/EndoSleeve, Gastric Balloon, MagDI), and medically supervised weight loss programs (GLP-1 injectables and oral medications) to patients with obesity. The practice performs most procedures on an outpatient basis at its Shoreline, Washington ambulatory surgery center and combines them with pre-operative evaluation, 12 months of aftercare, nutrition coaching, support groups, and a healow-based patient portal. Patients are treated through insurance coverage, self-pay packages with financing, or virtual consultations across the Pacific Northwest and beyond.

Product overview

Eviva offers a comprehensive weight loss care platform combining surgical, endoscopic, and medical weight loss solutions. The core offerings include three surgical procedures: Gastric Sleeve (LapSleeve®), Gastric Bypass, and Gastric Band (Lap-Band®), along with revision surgery for patients with prior procedures. The endoscopic portfolio features Endoscopic Sleeve Gastroplasty (ESG/EndoSleeve) and Gastric Balloon for non-surgical options, plus the 2026 MagDI procedure using magnetic technology. Medical weight loss encompasses injectable GLP-1 medications (Ozempic, Wegovy, Mounjaro) and oral medications (Phentermine, Contrave, Qsymia). Eviva provides integrated pre-surgical evaluation, surgical procedures, and long-term aftercare including nutrition coaching, support groups, and ongoing monitoring through their patient portal.

Differentiator

Problem solved

Functional benefit

Products and services

• Gastric Sleeve (LapSleeve) Laparoscopic sleeve gastrectomy that removes approximately 75-80% of the stomach, reducing it to a sleeve shape that limits food intake and reduces hunger hormones; yields 25-30% total body weight loss.
• Gastric Bypass (Roux-en-Y) Laparoscopic Roux-en-Y procedure that creates a small stomach pouch and reroutes the small intestine, reducing both food intake and calorie absorption; yields 30-35% total body weight loss within 12-18 months.
• Gastric Band (Lap-Band) Adjustable laparoscopic gastric banding placing an inflatable band around the upper stomach to create a small pouch that limits food intake; reversible and adjustable, yielding 15-20% total body weight loss.
• Endoscopic Sleeve Gastroplasty (ESG / EndoSleeve) Non-surgical endoscopic procedure using sutures to reduce stomach volume through the mouth without incisions; Eviva's Endosleeve+ enhancement uses 8-10 sutures for a tighter, more durable sleeve, achieving approximately 23% total body weight loss versus ~17% with standard ESG.
• Gastric Balloon Temporary non-surgical intragastric balloon placed endoscopically and filled with saline to occupy stomach space for approximately six months; aids in 10-15% total body weight loss during the placement period.
• MagDI (Magnetic Duodeno-Ileostomy) Minimally invasive bariatric procedure using magnetic compression anastomosis to create a connection between two parts of the small intestine, reducing calorie absorption without cutting, stapling, or leaving implants behind.
• Revision Surgery Laparoscopic and endoscopic revision procedures to modify, convert, or repair previous weight loss surgeries when initial results are inadequate or complications arise.
• Medical Weight Loss Program Clinically guided weight loss program combining FDA-approved injectable medications (Ozempic, Wegovy, semaglutide, Mounjaro, tirzepatide) and oral medications (Phentermine, Contrave, Qsymia, Vyvanse, Topiramate) with provider consultations and registered-dietitian visits on a subscription basis ($350 initial, then $150/month provider follow-ups and $75/month dietitian visits).
• Patient Portal (healow) Online patient portal (healow) enabling televisits, online form completion, medication refill requests, and payment processing for Eviva's weight loss patients.

Quantifiable outcome

• Gastric Bypass achieves 30-35% total body weight loss within 12-18 months
• +6 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• BLISCarecoreStrategic or Co-development PartnerBLISCare surgical complication coverage included in Eviva's self-pay surgical package, providing additional protection and peace of mind for patients beyond standard procedure coverage.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Surgery Partners: Surgery Partners (NASDAQ: SGRY) is one of the largest short-stay surgical facility operators in the U.S., with a portfolio that includes bariatric surgery centers. As an ASC chain operating in the same outpatient surgical space, it competes for outpatient bariatric volume and benefits from similar regulatory and accreditation dynamics.
• Found: Found is a digital weight loss platform combining prescription medication (including GLP-1s) with personalized coaching. It competes directly with Eviva's Medical Weight Loss Program for moderate-obesity patients who prefer non-surgical or telehealth-first treatment.
• Calibrate: Calibrate is a clinician-supervised metabolic health program that combines GLP-1 medication with one-on-one coaching. It targets the same medical weight loss segment as Eviva's medical program and competes for insured and self-pay patients seeking non-surgical obesity treatment.

Broad incumbents

• HCA Healthcare: HCA Healthcare (NYSE: HCA) operates 190+ hospitals and 2,400+ sites of care, including bariatric surgery programs across its facilities. It competes in the broader bariatric surgery market but offers bariatrics as one service line within a diversified portfolio.
• Tenet Healthcare: Tenet Healthcare (NYSE: THC) operates hospitals and the USPI ambulatory surgery network, both of which include bariatric surgery offerings. USPI specifically competes with Eviva in the outpatient ASC setting, while Tenet's hospital programs overlap with Eviva's surgical procedures.
• Medifast: Medifast (NYSE: MED) operates the OPTAVIA weight loss program focused on structured nutrition and coaching. While historically non-medical, Medifast has been expanding into medically supervised programs, putting it in adjacent competition with Eviva's medical weight loss offering.
• WW International: WW International (NYSE: WW) operates the Weight Watchers branded program and has expanded into GLP-1-supported weight management. It competes in the broader consumer weight loss category with Eviva, particularly for self-pay patients exploring non-surgical options.

Emerging players

• Hims & Hers Health: Hims & Hers Health (NYSE: HIMS) is a telehealth platform that recently expanded into weight loss with GLP-1 offerings. It competes for the same self-pay, digitally-engaged patient segment as Eviva's Medical Weight Loss Program, though it lacks any surgical offering.
• Ro: Ro is a direct-to-patient digital health platform that has expanded into weight management and GLP-1 prescribing. It competes with Eviva's medical weight loss subscription offering for self-pay patients preferring a fully online experience.

Others

• Eli Lilly: Eli Lilly (NYSE: LLY) manufactures Mounjaro and Zepbound (tirzepatide), the leading GLP-1 medications transforming obesity treatment. While not a direct competitor in surgical services, Lilly's therapeutics are increasingly displacing bariatric surgery for moderate obesity, fundamentally reshaping Eviva's addressable market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@evivamd
• Facebookfacebook.com/EvivaMD
• LinkedInlinkedin.com/company/puget-sound-surgical-cente
• Instagraminstagram.com/dr.vanderwel
• Xx.com/evivamd

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eviva